Tuoxin Pharmaceutical(301089.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Tuoxin Pharmaceutical
301089.SZ
Tuoxin Pharmaceutical Group Co.,Ltd. engages in the research and development, production and sales of nucleoside (acid) APIs and pharmaceutical intermediates in China. It offers nucleoside (acid) products, such as pyrimidine series, purine series, and nucleotide series; nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, azithromycin, cytosine, 5-fluorocytosine, cytidine, uridine; and other APIs and pharmaceutical intermediates covering antiviral, anti-tumor, and nervous system. The company was founded in 2001 and is based in Xinxiang, China.
3.143 T
301089.SZMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking205/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-3.07%D
    • Profit Margin-12.90%D
    • Gross Margin26.94%C
  • Growth ScoreD
    • Revenue YoY-11.48%E
    • Net Profit YoY34.88%B
    • Total Assets YoY-3.28%D
    • Net Assets YoY-2.97%D
  • Cash ScoreE
    • Cash Flow Margin-775.43%E
    • OCF YoY-11.48%E
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreA
    • Gearing Ratio9.89%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tuoxin Pharmaceutical: Net profit loss of 11.8805 million yuan in the third quarter, a decrease of 1,258.62%

    Tuoxin Pharmaceutical announced that the revenue for the third quarter was 89.6538 million yuan, a decrease of 16.21%; the net profit loss was 11.8805 million yuan, a decrease of 1,258.62%. The revenue for the first three quarters was 272 million yuan, a decrease of 16.64%; the net profit loss was 30.1611 million yuan, a decrease of 1,036.53%

    Zhitong·
    SZ
    301089
    -1.13%
    Zhitong·
    SZ
    301089
    -1.13%

    Tuoxin Pharmaceutical: Plans to establish a wholly-owned subsidiary with a registered capital of 50 million yuan

    Tuoxin Pharmaceutical announced that at the eighth meeting of the fifth board of directors held on October 28, 2025, it reviewed and approved the proposal for external investment to establish a subsidiary. The company plans to set up a wholly-owned subsidiary "Tuoxin Pharmaceutical Co., Ltd." in Tokto County, Hohhot City, Inner Mongolia Autonomous Region, with a registered capital of 50 million yuan. The new company will focus on the research and development, production, and sales of fermentation-related products, centered around the company's core business. The funds for this external investment will be entirely sourced from the company's own or self-raised funds, and the company will hold 100% equity

    Zhitong·
    SZ
    301089
    -1.13%
    Zhitong·
    SZ
    301089
    -1.13%

    Tuoxin Pharmaceutical's subsidiary product Glyceryl Phosphoryl Choline has passed the US Self-GRAS certification

    Tuoxin Pharmaceutical's wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has obtained Self-GRAS certification from the U.S. FDA for its product, Glycerophosphocholine. This product is a naturally occurring choline compound that offers several core benefits, including enhancing cognitive function, supporting brain health, improving athletic performance, and providing neuroprotection

    Zhitong·
    SZ
    301089
    -1.13%
    Zhitong·
    SZ
    301089
    -1.13%

    Tuoxin Pharmaceutical: Wholly-owned subsidiary obtains CNAS laboratory accreditation certificate

    Tuoxin Pharmaceutical announced that its wholly-owned subsidiary, Henan Nucleoside Drug Research Institute Co., Ltd., recently received a laboratory accreditation certificate granted by the China National Accreditation Service for Conformity Assessment. The name of the accredited organization is Henan Nucleoside Drug Research Institute Co., Ltd., and the registration number of the testing and inspection center is CNAS L23965, with an effective date of September 1, 2025, and an expiration date of August 31, 2031

    Zhitong·
    SZ
    301089
    -1.13%
    Zhitong·
    SZ
    301089
    -1.13%

    Tuoxin Pharmaceutical: Net loss of 18.2805 million yuan in the first half of 2025

    Tuoxin Pharmaceutical announced that its operating revenue in the first half of 2025 was 182 million yuan, a year-on-year decrease of 16.85%. The net loss was 18.2805 million yuan, compared to a loss of 1.7793 million yuan in the same period last year

    Zhitong·
    SZ
    301089
    -1.13%
    Zhitong·
    SZ
    301089
    -1.13%
    © 2026 Longbridge｜Disclaimer